Press Releases
iCAD Reports Financial Results For Second Quarter 2022
Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities Cancer Detection revenue grew 10.4% compared to the second quarter of 2021 Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – August 10, 2022 – iCAD, Inc….
iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022
NASHUA, N.H. – July, 27 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM…
iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology
Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women with 32 times higher risk of breast cancer than the general population NASHUA, N.H. – July 13, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today…
ProFound AI Risk Real-World Case Studies to be featured in iCAD’s “ProFound Insights, ProFound Impact” Webinar Series
Leading radiologists to highlight clinical examples demonstrating power of iCAD’s complete suite of ProFound AI Breast Health Solutions NASHUA, N.H. – June 29, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that leading radiologists will highlight clinical…
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Highlight ProFound AI Risk
Leading experts, including distinguished researchers from the Karolinska Institutet and clinicians using it in daily practice, to discuss significant impact and value of technology NASHUA, N.H. – June 7, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced…
iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022
NASHUA, N.H., June 6, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the JMP Securities Life Sciences Conference, taking place June 15-16, 2022 in New York City. Stacey Stevens, President and CEO of…
iCAD Announces CFO Transition
Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately NASHUA, N.H., May 25, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Stephen P. Sarno…
New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography
Research presented at the 2022 SBI/ACR Breast Imaging Symposium confirms ProFound AI significantly enhances radiologists’ screening performance NASHUA, N.H., May 18, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new research supporting ProFound AI® for Digital Breast…
New Research Finds iCAD’s ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population iCAD recently announced that promising clinical research supporting ProFound AI® Risk for Digital…
iCAD to Present at the Spring Into Action – Best Ideas Virtual Investor Conference on May 17th, 2022
NASHUA, N.H., May 12, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will present at the Spring Into Action – Best Ideas Virtual Investor Conference, which is being held virtually on May 16th – 20th, 2022….